MLYS Stock Mineralys Therapeutics, Inc.

$13.66
1d-3.53%5d-10.89%1m-35.26%ytd-62.36%
At close · Nov 20, 4:00 PM ET
After hours $13.66 +0% · Nov 20, 4:01 PM ET
52w low $13.570% of range$44.13 52w high
Price

Today’s call · MLYS

All live ideas →

6 of 6 technical checks lean bearish

MLYS is in a downtrend, momentum soft. $14 is the level overhead; $13 the first support below.

No open idea.From $13.66 the reward-to-risk to $13 against $14 is 1.9 — below the 3:1 bar.
What would create one:
  • A close below $13 on rising volume (breakdown).
  • A bounce to $14 that fails (entry near resistance).
Alert me at a level

The brief

Price vs 50-day · belowPrice vs 200-day · below50d vs 200d avg · belowMACD · bearishRSI momentum · 295-day tape · -10.9%
signalMLYS’s 50-day average is below the 200-day — long-term trend alignment is bearish.
levelPrice is 2.49% from resistance $14.0 — watch for a break or rejection.
momentumRSI 28.7 is oversold — the decline has been unusually fast.
All readings
TrendDowntrend · below 50-day & below 200-day
MomentumRSI 28.7 · oversold · MACD bearish
Trend strengthADX 26.7 · strong trend
Location-35.3% vs 50-day MA
52-week range-68% from high · +0% from low
VolatilityATR 1.19 · ~8.7%/day
RSI 14
28.7
MACD
-2.06
ADX 14
26.7
ATR 14
1.19
SMA 50
$21.12
SMA 200
$25.75

Levels that matter

$14round+2.5%
$15round+9.8%
$21.12sma 50+54.6%
$13round−4.8%
$12round−12.2%

Compare with…

Analyst overview · Nov 15

Mineralys Therapeutics (MLYS) stock analysis, November 15, 2026: Downtrend persists, breakout unlikely

Mineralys Therapeutics (MLYS) closed at $15.33 on November 13, well below its 52‑week low of $15.24 and its 40‑week average, confirming a prolonged downtrend. The daily price action follows the weekly decline, and the stock is lagging both the S&P 500 and the health‑care sector ETF XLV over the past 50 days. With a high conviction bearish stance for the next two to six weeks, the balance of evidence points to further downside unless a clear weekly close above $22.66 materialises.

Why it matters

The recent price slide reflects a broader market correction that has favoured large‑cap growth and left defensive health‑care names under pressure. Over the past five days the S&P 500 rose 2.59% while XLV gained 2.19%, yet MLYS posted a flat 0.0% change, leaving the stock 2.2 percentage points underperforming its sector. This underperformance is a key part of the story: the market rally has not lifted the shares, indicating that investors remain sceptical about the company’s near‑term prospects.

Volume has fallen 35% below its 20‑day average, suggesting a lack of buying interest even as the broader market climbs. The daily trend aligns with the weekly downtrend, and the 50‑day simple moving average sits at $22.66, a level that has acted as resistance in recent weeks. The stock’s relative strength index of 32.05 signals that the shares are approaching oversold territory, but the price remains above the 52‑week low, leaving little room for a technical bounce.

Analyst consensus is a strong‑buy with a mean target of $43.56, yet the current price is 64.8% below that target, highlighting a wide valuation gap. The spread between the consensus target and the market price underscores the disconnect between analyst optimism and market reality, especially given the stock’s lagging performance and deteriorating fundamentals.

There is no recent news to explain the move; the market has simply re‑priced the stock lower in line with its long‑term trend. The debate among commentators centres on whether the consensus target is still realistic. Some argue that the strong‑buy rating reflects a belief in upcoming product milestones, while others point to the stock’s failure to hold above $16 on rallies as evidence that sellers dominate. Both sides cite the same numbers – the $16 resistance, the $22.66 50‑day average, and the widening gap to analyst targets – but interpret them differently.

What the evidence says

On the long‑term horizon the thesis that MLYS is in a downtrend remains intact. The price is below both its 40‑week average and the 52‑week low, and the stock has lost 57.8% year‑to‑date. The weekly trend is clearly down, and the structure holds below $16, a round level where sellers have repeatedly stepped in.

For the next two to six weeks the balance of evidence leans negative with high conviction. The assessment notes three of four conviction points: the daily trend follows the weekly downtrend, the stock lags the S&P 500 by 31.4% over 50 days, and it lags XLV by 37.9% over the same period. The breakout math points to a downside breakout if the price closes below $15.24, with a stop at $16.39 and targets at $15.0 and $14.0. The reward‑to‑risk ratios are modest (0.2 and 1.1), and the trade does not meet a 3‑to‑1 risk‑reward threshold.

The strongest case against a further decline would be a rapid rally that pushes the price above $22.66 on a weekly close, which would signal a reversal of the weekly trend. However, such a move would require a swing of more than 40% from the current level, a scenario not supported by the current volume profile or sector momentum.

Levels that matter

The structure holds the stock below $16, a round level that has acted as a ceiling on several attempts to rally. Sellers have consistently appeared around this zone, reinforcing the downtrend. The weekly trend would only be considered ended if the price closes above $22.66, the 50‑day simple moving average, which also serves as a swing‑zone resistance.

The breakout level is the 52‑week low of $15.24. A daily close below this level would trigger the downside math: a stop at $16.39 (rounded $16 plus a quarter of the 14‑day ATR of $1.54) and targets at $15.0 and $14.0. The reward‑to‑risk on the first target is 0.2, and on the second it is 1.1, well short of the 3‑to‑1 ratio that would make the breakout statistically attractive. To achieve a 3‑to‑1 reward‑to‑risk the price would need to fall to roughly $13.0, a level not indicated by current support.

What would change the picture

A weekly close above $22.66, the 50‑day average, would invalidate the current downtrend narrative and suggest a new bullish phase. The non‑price catalyst that could drive such a move would be a materially positive earnings surprise or a breakthrough in the company’s pipeline that convinces investors the consensus targets are attainable.

What to watch

  • Next earnings release on November 5: the earnings per share figure will be the key metric to gauge whether the company can narrow the gap to analyst expectations.
  • Sector developments, especially FDA approvals or setbacks affecting biotech peers, which could shift XLV momentum and indirectly impact MLYS.
  • Valuation contrast: the consensus price target of $43.56 is 64.8% above the current price, highlighting a substantial disconnect that will only narrow if the stock shows clear upside momentum.

MarketCrew is AI-powered and can make mistakes — double-check before acting. Informational only, not investment advice.